Sarepta Therapeutics, Inc.
17.73USD
-0.4500 (-2.48%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SRPT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.36▼ | $0.48 | 0 | 1 |
| Next quarter | $0.12▼ | $0.43 | 0 | 1 |
| Current year | $4.32▼ | $4.79 | 0 | 1 |
| Next year | $2.45▲ | $2.45 | 0 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.49 | $0.64 | +0.15 (+31.7%) |
| 2026-03-31 | $1.05 | $3.16 | +2.11 (+202.1%) |
| 2025-12-31 | -$0.77 | -$3.58 | -2.81 (-365.3%) |
| 2025-09-30 | -$0.37 | -$0.13 | +0.24 (+65.0%) |
497 ratings from 47 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Sector Perform | $19 $17 | Oct 8, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Oct 5, 2026 |
| JP Morgan | Maintained | Neutral | $23 $20 | Sep 30, 2026 |
| Needham | Reiterated | Underperform | — | Sep 28, 2026 |
| Piper Sandler | Maintained | Neutral | $23 $20 | Jul 9, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $27 | Jul 9, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Apr 16, 2026 |
| Citigroup | Maintained | Sell | $9 $13 | Mar 26, 2026 |
| Needham | Reiterated | Underperform | — | Mar 26, 2026 |
| Oppenheimer | Reiterated | Outperform | $37 | Mar 19, 2026 |
| Mizuho | Maintained | Outperform | $26 $31 | Mar 13, 2026 |
| Citigroup | Maintained | Sell | $8 $9 | Mar 10, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Mar 2, 2026 |
| Wells Fargo | Maintained | Overweight | $45 $38 | Feb 27, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Jan 27, 2026 |
| Wedbush | Maintained | Outperform | $32 $34 | Jan 23, 2026 |
| HC Wainwright & Co. | Reiterated | Sell | $5 | Jan 14, 2026 |
| Wedbush | Initiated | Outperform | $32 | Dec 9, 2025 |
| Barclays | Maintained | Equal-Weight | $22 $20 | Nov 5, 2025 |
| Wells Fargo | Maintained | Overweight | $50 $45 | Nov 5, 2025 |
| Guggenheim | Maintained | Buy | $22 $19 | Nov 5, 2025 |
| Mizuho | Upgraded from Neutral | Outperform | $19 $26 | Nov 5, 2025 |
| Baird | Maintained | Neutral | $21 $15 | Nov 4, 2025 |
| Piper Sandler | Maintained | Neutral | $15 $16 | Oct 30, 2025 |
| BMO Capital | Upgraded from Market Perform | Outperform | $50 | Sep 22, 2025 |
58 filings from 20 insiders · 0 buy / 0 sell over 6m
Officers and directors of SRPT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Wong Ryan Ho-YanOfficer, Chief Financial Officer | Tax | 13.3k | $22.22 | $295k | Sep 4, 2026 |
| Estepan Ian MichaelOfficer, Chief Operating Officer | Tax | 24.8k | $22.22 | $551k | Sep 4, 2026 |
| Rothfuss CristinOfficer, EVP, General Counsel | Tax | 22.0k | $22.22 | $489k | Sep 4, 2026 |
| Rodino-Klapac LouiseOfficer, President, R&D and Tech Ops | Tax | 21.4k | $22.22 | $476k | Sep 4, 2026 |
| SEVERINO MICHAEL EChief Executive Officer | Grant | 756.1k | — | — | Jul 28, 2026 |
| BEHRENS M KATHLEENDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| CHAMBERS MICHAEL ANDREWDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| WIGZELL HANS LENNART RUDOLFDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| CONNELLY DEIRDRE PDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| BARRY RICHARD JDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| NICAISE CLAUDEDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| BOOR KATHRYN JEANDirector | Grant | 16.9k | — | — | Jun 4, 2026 |
| MAYO STEPHEN L.Director | Grant | 16.9k | — | — | Jun 4, 2026 |
| MAYO STEPHEN L.Director | Sell | 7.2k | $17.02 | $123k | Mar 12, 2026 |
| RODINO-KLAPAC LOUISEOfficer | Other | 8.1k | — | — | Feb 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Other | 8.1k | — | — | Feb 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Exercise | 7.5k | $13.71 | $102k | Feb 26, 2026 |
| NICAISE CLAUDEDirector | Exercise | 10.5k | $13.71 | $144k | Jan 29, 2026 |
| BEHRENS M KATHLEENDirector | Exercise | 10.5k | $13.71 | $144k | Jan 27, 2026 |
| ESTEPAN IAN MICHAELChief Operating Officer | Sell | 13.2k | $22.31 | $294k | Dec 16, 2025 |
No analyst notes on SRPT yet.
Analyst Ratings
22 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 7 | 12 | 3 | 2 | Hold3.00 |
| 1 mo ago | 0 | 7 | 12 | 3 | 2 | Hold3.00 |
| 2 mo ago | 0 | 8 | 11 | 3 | 2 | Hold2.96 |
| 3 mo ago | 0 | 8 | 11 | 3 | 2 | Hold2.96 |
Members whose judged calls on SRPT have played out most reliably.
No settled calls on SRPT yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice